4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10 ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will ...

Ensifentrine was approved on June 26, so this is its first full quarter of launch. Branded as Ohtuvayre, the FDA label had no surprises and no boxed warnings or REMS. The FDA label simply said ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on LGND stock, giving a Buy rating on December 3.Pick the best ...

This outperformance was partly driven by $10.1 million in milestone payments, attributed to FDA approvals of Ohtuvayre and Capvaxive, as well as the conditional marketing approval of Filspari by ...

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the ...

Ligand's pipeline has seen significant progress in recent months, with notable approvals including Ohtuvayre and Capvaxive by the FDA, as well as the conditional marketing approval of Filspari by the ...

This outperformance was partly driven by $10.1 million in milestone payments, attributed to FDA approvals of Ohtuvayre and Capvaxive, as well as the conditional marketing approval of Filspari by the ...

The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...